| Latest Forum Topics / Clearbridge Last:0.002 -- |
|
|
Medical Stock - Strong Shareholders
|
|||||
|
memyselfi
Senior |
22-Apr-2020 16:21
|
||||
|
x 0
x 0 Alert Admin |
im guessing its good news for bio... if not price would have fallen by quite a % here.. see how | ||||
| Useful To Me Not Useful To Me | |||||
|
AttasBoss
Elite |
22-Apr-2020 16:16
|
||||
|
x 0
x 0 Alert Admin |
why on bio halt but clearbrige as a main shareholder doesn" t halt? if good news then should joint halt right? |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
lovetoshare
Elite |
22-Apr-2020 16:13
|
||||
|
x 0
x 0 Alert Admin |
if no, then ceo knows parent company tag on Biolidics success for this time.... so after this back to normal ba
|
||||
| Useful To Me Not Useful To Me | |||||
|
Astroman
Member |
22-Apr-2020 16:04
|
||||
|
x 0
x 0 Alert Admin |
Clearbridge has gone as much as 60cents before even without much good news. Think if this time new news from Biolidics are good, I?m not surprised that Clearbridge will go far as they are majority share holders of Biolidics. | ||||
| Useful To Me Not Useful To Me | |||||
|
Kofrules
Member |
22-Apr-2020 15:56
|
||||
|
x 0
x 0 Alert Admin |
Should sell now at 0.24 or will go higher | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
wolverine23
Supreme |
22-Apr-2020 13:58
Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!" |
||||
|
x 0
x 0 Alert Admin |
i think 35 rather than 25
|
||||
| Useful To Me Not Useful To Me | |||||
|
Elf2000
Elite |
22-Apr-2020 13:57
|
||||
|
x 0
x 0 Alert Admin |
Clearbridge Health and its wholly-owned subsidiary Clearbridge BSA hold a combined 46.14 per cent stake in Biolidics as at March 18, according to Biolidics' annual report.
Asked by The Business Times if there was a development at Clearbridge that might explain the increase in its share price, group chief executive officer Jeremy Yee said no, but noted that Clearbridge is a shareholder of Biolidics.
|
||||
| Useful To Me Not Useful To Me | |||||
|
dollarsense
Veteran |
22-Apr-2020 13:56
|
||||
|
x 0
x 0 Alert Admin |
cant clear 25? | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Elf2000
Elite |
22-Apr-2020 13:55
|
||||
|
x 0
x 0 Alert Admin |
https://www.businesstimes.com.sg/companies-markets/hot-stock-covid-19-test-maker-biolidics-sees-546-jump-in-share-price | ||||
| Useful To Me Not Useful To Me | |||||
|
jnplee
Member |
17-Apr-2020 22:48
|
||||
|
x 0
x 0 Alert Admin |
德 国 口 罩 价 格 飙 涨 https://www.zaobao.com/realtime/world/story20200417-1046318?utm_source=ZB_Android&utm_medium=share
|
||||
| Useful To Me Not Useful To Me | |||||
|
jnplee
Member |
17-Apr-2020 22:47
|
||||
|
x 0
x 0 Alert Admin |
https://www.trigema.de/en/Protective-clothing/Reusable-mouth-and-nose-protection-to-tie-white-1.html
|
||||
| Useful To Me Not Useful To Me | |||||
|
lovetoshare
Elite |
17-Apr-2020 20:41
|
||||
|
x 0
x 0 Alert Admin |
you look at the directors you will know. Anyhow anyhow type. you see the chart... dont know how he leadership one... every year down..
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
goldeneye
Senior |
23-Jan-2020 07:19
|
||||
|
x 0
x 0 Alert Admin |
🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀 | ||||
| Useful To Me Not Useful To Me | |||||
|
lovetoshare
Elite |
23-Jan-2020 06:04
|
||||
|
x 0
x 0 Alert Admin |
why this penny stock Up and Down so many times in a day ? Good or Poor stock?.... | ||||
| Useful To Me Not Useful To Me | |||||
|
goldeneye
Senior |
22-Jan-2020 21:26
|
||||
|
x 0
x 0 Alert Admin |
Do self a service Watch Glued Closely as it&rsquo s  otw . .. cumming ! |
||||
| Useful To Me Not Useful To Me | |||||
|
goldeneye
Senior |
22-Jan-2020 18:54
|
||||
|
x 0
x 0 Alert Admin |
🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 | ||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
22-Jan-2020 10:16
|
||||
|
x 0
x 0 Alert Admin |
Healthcare stocks get a shot in the arm as Wuhan virus fears rise
 
  The outbreak of a new SARS-like virus originating in Wuhan, the capital of China&rsquo s Hubei province, is putting Asian stock markets on edge.
By Jan 21, four people have died from the virus, as 15 Chinese medical workers were reported to have been infected after treating infected patients.
 
The World Health Organization has confirmed that the pathogen, known as 2019-nCoV, is being transmitted among humans.
 
It had been originally hoped that transmission of the virus was limited from animals to humans, as some of the first patients worked or shopped at a seafood market in Wuhan where live animals and wildlife parts were also reportedly sold.
 
&ldquo The outbreak of a SARS-like coronavirus in Wuhan is developing into a major potential economic risk to the Asia-Pacific region now that there is medical evidence of human-to-human transmission,&rdquo says Rajiv Biswas, chief economist for Asia Pacific at IHS Markit.
 
&ldquo With a number of Wuhan virus cases having already been detected outside of China, this outbreak is particularly concerning just as the Chinese New Year season gets underway, with millions of Chinese tourists travelling both within China and to many popular Asian tourist destinations, such as Thailand, Vietnam, Japan, Singapore and South Korea,&rdquo he adds.
 
Already, confirmed coronavirus cases have been identified in Thailand, Japan and South Korea.
 
&ldquo Asia will remember back to the origins of SARS outbreak and its adverse effects on economic activity in the region. It is, therefore, no surprise that both equities and oil are being marked lower across Asia today,&rdquo says Jeffrey Halley, senior market analyst for Asia Pacific at OANDA.
 
The way Halley sees it, the price action in Asia is &ldquo a window to the future&rdquo if the pneumonia outbreak escalates. &ldquo We would expect Asian equities, currencies, and also energy, to all come under pressure on lower growth fears for the region,&rdquo he adds.
 
In contrast, fears of the spread of the Wuhan virus is giving some healthcare stocks a shot in the arm.
 
Healthcare names were the best performers in the MSCI China Index on Monday, with the sector rising 1.3%. Antibiotics makers Jiangsu Lianhuan Pharmaceutical Co, Shandong Lukang Pharmaceutical Co and Shenzhen Neptunus Bioengineering Co all climbed the 10% daily limit.
In Singapore, Healthway Medical Corporation, the private outpatient medical service provider with more than 80 clinics across the island, led the way on Tuesday, surging 42.9% to a new 52-week-high of 4 cents as at 12pm.
 
Shares in Medtecs International Corporation, the manufacturer and distributor of medical consumables for the healthcare industry, also ascended to a 52-week peak, jumping 26.9% to 6.6 cents as at 12 pm.
 
Meanwhile, AsiaMedic, a healthcare provider that focuses on the management of clinical services in the fields of disease prevention, early illness detection and advanced diagnostics, soared 23.1% to 1.6 cents.
 
Other healthcare counters, including Clearbridge Health, Singapore Medical Group, UG Healthcare Corporation, and Thomson Medical Group, were also among the biggest climbers for the day &ndash rising 5.2%, 5.0%, 3.7%, and 3.2%, respectively.
 
Apart from the healthcare sector, however, IHS Markit&rsquo s Biswas warns that some other sectors of the economy could be &ldquo particularly vulnerable&rdquo to a SARS-like virus epidemic that can be spread by human-to-human transmission. These include retail stores, restaurants, conferences, sporting events, tourism and commercial aviation, he says.
 
&ldquo A key concern is the potential risk for the Tokyo Summer Olympics in July-August 2020,&rdquo Biswas adds. &ldquo Therefore, containing the current Wuhan virus outbreak has become a key priority for Chinese and international health care authorities, with enhanced screening of travellers now being put into place in many major airports worldwide.&rdquo
|
||||
| Useful To Me Not Useful To Me | |||||
|
Wind22i
Supreme |
22-Jan-2020 09:22
|
||||
|
x 0
x 0 Alert Admin |
can see some rotation into other med stocks like this one | ||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
14-Jan-2020 09:42
|
||||
|
x 0
x 0 Alert Admin |
Global health industry&rsquo s $1t war chest to drive 2020 deal boom: EY  https://www.dealstreetasia.com/stories/health-industry-2020-deal-boom-ey-170140/?mc_cid=468d0b2627& mc_eid=62c70c6de8 The health industry&rsquo s more than $1 trillion in &ldquo firepower&rdquo should deliver another strong year for deals, a new report shows. Big biotechnology firms and their medical technology brethren will be active dealmakers in 2020 as companies look to fuel needed growth, according to a report released Monday by professional services firm EY. Cell and gene therapy firms are expected to continue to dominate biotech deals. EY sees the potential for almost $300 billion in deals even without a repeat of 2019&rsquo s mega-mergers. &ldquo To continue the record-setting M& A trajectory, companies outside big pharma must return to the dealmaking table and make transformative bets of their own,&rdquo analysts led by Pamela Spence and Peter Behner wrote. Their findings suggest that most of the largest biopharma companies have the ability to do bolt-on deals with about one-third having the capacity for mega-mergers, defined as transformative deals with valuations of at least $40 billion for biopharma and $10 billion for medtech.  The report comes just hours before the annual JPMorgan Healthcare Conference kicks off in San Francisco. The event has long been a top spot for companies to showcase new deals and for executives to rub elbows with bankers and lawyers. In a September survey, 94% of respondents told EY that they expect deals to either increase or stay flat over the next year. The normal benchmark for biotech and medical technology deals since 2015 is about $200 billion a year.  &ldquo Firepower remains plentiful and we expect to see more activity in medtech and big biotech, with mega-mergers coming from companies with acute growth gaps,&rdquo Behner said in a statement. &ldquo Market volatility and the desire to deepen therapeutic focus will continue to be deal catalysts in 2020.&rdquo The firm defines &ldquo firepower&rdquo as a company&rsquo s capacity to fund deals, including its cash, existing debt, debt capacity and market valuation.  Large biotech companies have historically preferred to return cash to investors via share buybacks rather than deals. Share repurchases and research and development accounted for roughly 80% of their spending in 2019 compared to just 9% on mergers and acquisitions. |
||||
| Useful To Me Not Useful To Me | |||||
|
WBdisciple
Elite |
28-Dec-2019 08:48
|
||||
|
x 0
x 0 Alert Admin |
CBH has entered the fast-growing healthcare markets in Indonesia and the Philippines through two acquisitions.  http://www.hnworth.com/article/invest/brokers-picks/clearbridge-health-limited/ Both countries rank among the lowest in Asia in terms of the number of hospital beds and health professionals per capita. Healthcare spending in both countries has been growing at around 9 &ndash 10% p.a. A key feature of its new Indonesian business is recurring revenue. Renal dialysis is a lifetime treatment, and CBH expanded from 15 hospitals at acquisition to 21 currently and another 13 under renovation. CBH acquires asset-light, fast-growing healthcare segments. After the acquisition, CBH grows the businesses through expansion in capacity, network and capabilities. Maintain BUY with an unchanged target price of S$0.26. We used DCF valuation to capture the full benefit of CBH impressive growth over the next five years. Closing Price: S$0.14 |
||||
| Useful To Me Not Useful To Me | |||||

